Ongoing initiatives to improve prescribing efficiency in China: statins as a case history

Wenjie Zeng, Houmei Xi, Brian Godman, Alexander E Finlayson, Rickard E Malmstrom

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pharmaceutical expenditure rose by 16% per annum in China during the past decade, and now represents 46% of total healthcare expenditure. Initiatives to moderate growth include pricing regulations for pharmaceuticals and encouraging International Nonproprietary Name (INN) prescribing. However, there is limited monitoring of physician prescribing and current incentives encourage hospitals and physicians to profit from drug procurement. The objective was to assess changes in statin utilization and expenditure as additional generics are launched. Subsequently, compare results in China with findings among European countries to provide future guidance. We used observational retrospective study of statin utilization and procurement expenditure from 2004 to 2013 in two large teaching hospital groups. The results were that statin utilization rose 32-fold in one hospital group and 54-fold in the other. Expenditure also increased but to a lesser extent, i.e. from just over Renminbi ‘yuan’ (CNY) 0.65 million in 2004 to CNY 15.3 million in 2013 in one hospital group and from CNY 0.49 to CNY 19.3 million in the other. Atorvastatin (originator) was the most utilized statin. Utilization of each generic statin was typically low, e.g. 10% in 2013 in one hospital group. Procurement prices fell over time, greatest for generic simvastatin (-74% to -91%) mirroring data from European countries. However, no increase in their prescribing was observed. In fact, a significant decrease in generic prescribing was seen in one hospital group between 2004 and 2013. There are considerable opportunities to improve prescribing efficiency in China based on European experience. However, current incentives encouraging hospitals and physicians to profit from drug procurement need to be addressed.
LanguageEnglish
Pages122-132
Number of pages11
JournalGenerics and Biosimilars Initiative journal
Volume3
Issue number3
Early online date1 Sep 2014
DOIs
Publication statusPublished - Sep 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Health Expenditures
China
Physicians
Pharmaceutical Preparations
Motivation
Profitability
Simvastatin
Teaching Hospitals
Names
Observational Studies
Retrospective Studies
Teaching
Delivery of Health Care
Costs and Cost Analysis
Growth
Monitoring

Keywords

  • China
  • drug utilization study
  • health policies
  • pharmaceuticals
  • prices
  • statins

Cite this

Zeng, Wenjie ; Xi, Houmei ; Godman, Brian ; Finlayson, Alexander E ; Malmstrom, Rickard E. / Ongoing initiatives to improve prescribing efficiency in China : statins as a case history. In: Generics and Biosimilars Initiative journal. 2014 ; Vol. 3, No. 3. pp. 122-132.
@article{a2a51b972998411e870612a607a39371,
title = "Ongoing initiatives to improve prescribing efficiency in China: statins as a case history",
abstract = "Pharmaceutical expenditure rose by 16{\%} per annum in China during the past decade, and now represents 46{\%} of total healthcare expenditure. Initiatives to moderate growth include pricing regulations for pharmaceuticals and encouraging International Nonproprietary Name (INN) prescribing. However, there is limited monitoring of physician prescribing and current incentives encourage hospitals and physicians to profit from drug procurement. The objective was to assess changes in statin utilization and expenditure as additional generics are launched. Subsequently, compare results in China with findings among European countries to provide future guidance. We used observational retrospective study of statin utilization and procurement expenditure from 2004 to 2013 in two large teaching hospital groups. The results were that statin utilization rose 32-fold in one hospital group and 54-fold in the other. Expenditure also increased but to a lesser extent, i.e. from just over Renminbi ‘yuan’ (CNY) 0.65 million in 2004 to CNY 15.3 million in 2013 in one hospital group and from CNY 0.49 to CNY 19.3 million in the other. Atorvastatin (originator) was the most utilized statin. Utilization of each generic statin was typically low, e.g. 10{\%} in 2013 in one hospital group. Procurement prices fell over time, greatest for generic simvastatin (-74{\%} to -91{\%}) mirroring data from European countries. However, no increase in their prescribing was observed. In fact, a significant decrease in generic prescribing was seen in one hospital group between 2004 and 2013. There are considerable opportunities to improve prescribing efficiency in China based on European experience. However, current incentives encouraging hospitals and physicians to profit from drug procurement need to be addressed.",
keywords = "China, drug utilization study, health policies, pharmaceuticals, prices, statins",
author = "Wenjie Zeng and Houmei Xi and Brian Godman and Finlayson, {Alexander E} and Malmstrom, {Rickard E}",
year = "2014",
month = "9",
doi = "10.5639/gabij.2014.0303.030",
language = "English",
volume = "3",
pages = "122--132",
journal = "Generics and Biosimilars Initiative journal",
issn = "2033-6403",
number = "3",

}

Ongoing initiatives to improve prescribing efficiency in China : statins as a case history. / Zeng, Wenjie; Xi, Houmei; Godman, Brian; Finlayson, Alexander E; Malmstrom, Rickard E.

In: Generics and Biosimilars Initiative journal, Vol. 3, No. 3, 09.2014, p. 122-132.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ongoing initiatives to improve prescribing efficiency in China

T2 - Generics and Biosimilars Initiative journal

AU - Zeng, Wenjie

AU - Xi, Houmei

AU - Godman, Brian

AU - Finlayson, Alexander E

AU - Malmstrom, Rickard E

PY - 2014/9

Y1 - 2014/9

N2 - Pharmaceutical expenditure rose by 16% per annum in China during the past decade, and now represents 46% of total healthcare expenditure. Initiatives to moderate growth include pricing regulations for pharmaceuticals and encouraging International Nonproprietary Name (INN) prescribing. However, there is limited monitoring of physician prescribing and current incentives encourage hospitals and physicians to profit from drug procurement. The objective was to assess changes in statin utilization and expenditure as additional generics are launched. Subsequently, compare results in China with findings among European countries to provide future guidance. We used observational retrospective study of statin utilization and procurement expenditure from 2004 to 2013 in two large teaching hospital groups. The results were that statin utilization rose 32-fold in one hospital group and 54-fold in the other. Expenditure also increased but to a lesser extent, i.e. from just over Renminbi ‘yuan’ (CNY) 0.65 million in 2004 to CNY 15.3 million in 2013 in one hospital group and from CNY 0.49 to CNY 19.3 million in the other. Atorvastatin (originator) was the most utilized statin. Utilization of each generic statin was typically low, e.g. 10% in 2013 in one hospital group. Procurement prices fell over time, greatest for generic simvastatin (-74% to -91%) mirroring data from European countries. However, no increase in their prescribing was observed. In fact, a significant decrease in generic prescribing was seen in one hospital group between 2004 and 2013. There are considerable opportunities to improve prescribing efficiency in China based on European experience. However, current incentives encouraging hospitals and physicians to profit from drug procurement need to be addressed.

AB - Pharmaceutical expenditure rose by 16% per annum in China during the past decade, and now represents 46% of total healthcare expenditure. Initiatives to moderate growth include pricing regulations for pharmaceuticals and encouraging International Nonproprietary Name (INN) prescribing. However, there is limited monitoring of physician prescribing and current incentives encourage hospitals and physicians to profit from drug procurement. The objective was to assess changes in statin utilization and expenditure as additional generics are launched. Subsequently, compare results in China with findings among European countries to provide future guidance. We used observational retrospective study of statin utilization and procurement expenditure from 2004 to 2013 in two large teaching hospital groups. The results were that statin utilization rose 32-fold in one hospital group and 54-fold in the other. Expenditure also increased but to a lesser extent, i.e. from just over Renminbi ‘yuan’ (CNY) 0.65 million in 2004 to CNY 15.3 million in 2013 in one hospital group and from CNY 0.49 to CNY 19.3 million in the other. Atorvastatin (originator) was the most utilized statin. Utilization of each generic statin was typically low, e.g. 10% in 2013 in one hospital group. Procurement prices fell over time, greatest for generic simvastatin (-74% to -91%) mirroring data from European countries. However, no increase in their prescribing was observed. In fact, a significant decrease in generic prescribing was seen in one hospital group between 2004 and 2013. There are considerable opportunities to improve prescribing efficiency in China based on European experience. However, current incentives encouraging hospitals and physicians to profit from drug procurement need to be addressed.

KW - China

KW - drug utilization study

KW - health policies

KW - pharmaceuticals

KW - prices

KW - statins

UR - http://gabi-journal.net/ongoing-initiatives-to-improve-prescribing-efficiency-in-china-statins-as-a-case-history.html

U2 - 10.5639/gabij.2014.0303.030

DO - 10.5639/gabij.2014.0303.030

M3 - Article

VL - 3

SP - 122

EP - 132

JO - Generics and Biosimilars Initiative journal

JF - Generics and Biosimilars Initiative journal

SN - 2033-6403

IS - 3

ER -